Hizuka N, Takano K, Shizume K, Asakawa K, Miyakawa M, Tanaka I, Horikawa R
Eur J Pharmacol. 1986 Jun 5;125(1):143-6. doi: 10.1016/0014-2999(86)90093-2.
The scarcity of purified somatomedin/insulin-like growth factor (SM/IGF) has prevented investigation of the mechanisms of SM/IGF action. Recently insulin-like growth factor I (IGF-I) has been synthesized by recombinant DNA technology. The availability of large quantities of the biosynthetic IGF-I made it possible to study its effects by administering 120 micrograms/day via s.c. implanted minipump to rats for 7 days. After this 7 day administration of IGF-I, the body weight increased to 197.6 +/- 3.5% of initial values; the value was significantly greater than that of the control (179.4 +/- 3.7% of initial values, P less than 0.01). The body length and tibial epiphyseal width in IGF-I-treated rats were also significantly increased over those of control rats. The weights of kidneys, liver, testes and pituitary in IGF-I-treated rats were greater than those in control rats as well. These results provide a first demonstration that IGF-I stimulates growth in normal rats in vivo, and suggest that IGF-I might be useful in the treatment of growth retardation.
纯化的生长调节素/胰岛素样生长因子(SM/IGF)的稀缺阻碍了对SM/IGF作用机制的研究。最近,胰岛素样生长因子I(IGF-I)已通过重组DNA技术合成。大量生物合成的IGF-I的可得性使得通过皮下植入微型泵以每天120微克的剂量给大鼠给药7天来研究其作用成为可能。在对IGF-I进行这7天的给药后,体重增加到初始值的197.6±3.5%;该值显著高于对照组(初始值的179.4±3.7%,P<0.01)。经IGF-I处理的大鼠的体长和胫骨骨骺宽度也比对照大鼠显著增加。经IGF-I处理的大鼠的肾脏、肝脏、睾丸和垂体的重量也大于对照大鼠。这些结果首次证明IGF-I在体内刺激正常大鼠生长,并表明IGF-I可能对治疗生长迟缓有用。